Also trades as: 0IV3.L (LSE) · $vol 0M
GERN NASDAQ
Geron Corporation
1W: -12.9%
1M: -21.8%
3M: -37.1%
YTD: -7.6%
1Y: -3.9%
3Y: -57.8%
5Y: -12.2%
$1.22
-0.01 (-0.81%)
Pre-Market: $1.23 (+0.01, +1.23%)
Weekly Expected Move ±8.3%
$1
$1
$1
$1
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$782.7M
52W Range1.04-2.01
Volume10,351,491
Avg Volume19,128,685
Beta0.68
Dividend—
Analyst Ratings
Company Info
CEOHarout Semerjian
Employees229
SectorHealthcare
IndustryBiotechnology
IPO Date1996-07-31
Websitegeron.com
919 East Hillsdale Boulevard
Foster City, CA 94404
US
Foster City, CA 94404
US
650 473 7700
About Geron Corporation
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Latest News
Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026
Geron (GERN) Q1 2026 Earnings Call Transcript
Earnings Scheduled For May 6, 2026
Geron targets $220M-$240M 2026 RYTELO net revenue while weighing new Europe commercialization models
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Williams Timothy | A-Award | 2,500,000 | $1.73 | 2026-04-13 |
| Williams Timothy | 0 | — | 2026-04-13 | |
| Spiegel Robert J. | A-Award | 5,243 | $1.49 | 2026-03-31 |
| Chinoporos Constanti | A-Award | 270,000 | $1.57 | 2026-03-25 |
| Chinoporos Constanti | 0 | — | 2026-03-25 |